Your weekly roundup of the latest news from Drug Topics®.
According to a recent study, the diabetes medication semaglutide is more effective as a 25 mg or 50 mg dose on its own, rather than a 14 mg add-on dose with other medications.
The drug, branded as Rezzayo, is the first FDA-approved invasive candidiasis treatment in over a decade.
Two posters presented at APhA in Phoenix examined the efficacy of the Omnipod® 5 Automated Insulin Delivery System.
COVID-19 misinformation is common. A study presented at the annual APhA meeting examined how new pharmacy practitioners responded to misinformation and tried to minimize its spread.
Pharmacists can provide support and guidance to patients during their month of fasting.
FDA Approves Second Formulation of Humira Biosimilar Cyltezo
May 1st 2024According to Michael Osso, president and chief executive officer of the Crohn’s & Colitis Foundation, “the flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicine.”